Voyager Therapeutics Inc - VYGR Net earnings per share for the trailing year

Voyager Therapeutics (VYGR) bases its competitive advantage on the commercialization of the Tracer system for viral capsid discovery and lucrative contracts with pharmaceutical leaders. Business revenues rely on licensing fees and royalties for the application of drug delivery technologies to the brain. The company's price chart reflects EPS TTM dynamics, which currently stand at 19.50. However, geopolitical tensions and sanctions are hindering logistics and global clinical trials.
Financial and market metric breakdowns for Voyager Pharma (VYGR)

Geopolitical fragmentation and sanctions are hindering the global clinical trials of gene therapies conducted by Voyager Therapeutics (VYGR). This metric reflects the annual trend of net income per share over the last twelve months, measuring the efficiency of asset monetization. Analyzing the relative change in EPS YoY (TTM) allows for an assessment of how external restrictions impact business profitability. The negative trend of this curve signals a high probability of capital impairment.